Crusia (Enoxaparin Sodium)

Enoxaparin Sodium works by binding to antithrombin III, a natural protein in the blood that inhibits blood clotting. This binding potentiates the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), thereby reducing the blood's ability to form clots. This mechanism makes it effective in preventing and treating thromboembolic events.

The dosage of Crusia is determined by a healthcare provider based on the patient's condition, weight, and other factors. It is crucial to follow the prescribed dosage and administration instructions provided by the healthcare professional to ensure safety and effectiveness.

The safety of Crusia during pregnancy or breastfeeding should be discussed with a healthcare provider. While it is often used in pregnant women at risk of blood clots, the decision to use it should be based on a thorough evaluation of the benefits and risks by a medical professional.

To order Crusia from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask the buyer to confirm trade or institutional credentials and will reply with pricing, availability, shipping, and the import paperwork.

Crusia is a low molecular weight heparin, which offers several advantages over traditional anticoagulants like warfarin. It has a more predictable anticoagulant effect, requires less frequent monitoring, and has a lower risk of certain side effects. However, the choice of anticoagulant depends on the specific needs and conditions of the patient.

Crusia should be stored below 25°C, kept in the original pack, and protected from moisture and light. It should not be frozen. Proper storage and handling are essential to maintain the effectiveness and safety of the medication. Always follow the storage instructions provided on the packaging.

Crusia is typically administered via subcutaneous injection or intravenous infusion, depending on the clinical setting and the patient's needs. The administration should be carried out by a healthcare professional to ensure proper dosage and technique. Always follow the administration instructions provided by the healthcare provider.

The most serious risks associated with Crusia include severe bleeding, allergic reactions, and thrombocytopenia. Patients should be monitored regularly for signs of bleeding, and any unusual symptoms should be reported to a healthcare provider immediately. Regular blood tests may be required to monitor clotting times and platelet counts.

Crusia should not be used by individuals with a known hypersensitivity to Enoxaparin Sodium or other low molecular weight heparins. It should also be used with caution in patients with a history of bleeding disorders, severe liver or kidney disease, or those undergoing major surgery. Always consult a healthcare provider before starting Crusia.